Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EPS (Weighted Average and Diluted) (2020 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$7.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 27.61% year-over-year to -$7.0, compared with a TTM value of -$17.93 through Dec 2025, down 28.07%, and an annual FY2025 reading of -$17.93, down 28.07% over the prior year.
  • EPS (Weighted Average and Diluted) was -$7.0 for Q4 2025 at Karyopharm Therapeutics, down from -$3.84 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.51 in Q4 2021 and bottomed at -$17.9 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.82, with a median of -$0.62 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 685.6% in 2021, then crashed 4161.9% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.51 in 2021, then tumbled by 181.59% to -$0.42 in 2022, then plummeted by 4161.9% to -$17.9 in 2023, then skyrocketed by 45.98% to -$9.67 in 2024, then grew by 27.61% to -$7.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KPTI at -$7.0 in Q4 2025, -$3.84 in Q3 2025, and -$4.32 in Q2 2025.